Lexeo reports interim data for heart condition gene therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. NEST:IN
10. AA

Go back to Lexeo reports interim data for heart condition gene therapy

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

January 12, 2026 7:00 AM EST

LX2020 generally well tolerated across ten participants with no clinically significant complement activation 

LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts

Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions

Company to host webcast today at 8:00 AM ET / 5:00 AM PT

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) --... More